Gestrinone in mastalgia: A randomized double blind placebo controlled trial

Robert C. Stein, Nigel S. B. Rawson, J.-C. Gazet, H.T. Ford, R. Charles Coombes
In: The Breast · 1994 · vol. 3(2) , pp. 90–93 · doi:10.1016/0960-9776(94)90005-1 · W2019101882
article OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Gestrinone treatment significantly reduced mastalgia in patients with benign breast disease compared to placebo over three months, despite increased side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

78 patients with mastalgia associated with benign breast disease were randomized to treatment with the synthetic steroid gestrinone (2.5 mg twice weekly) or placebo for 3 months. Breast pain scores, which were similar in the two groups prior to treatment, were lowered significantly in patients receiving gestrinone after each month of treatment. After 1 month, 65% of patients in the gestrinone arm considered that their treatment was either excellent or good compared with 23% in the placebo arm (p < 0.01). High levels of satisfaction with gestrinone were also recorded at 2 and 3 months. Investigator opinion of treatment was also significantly in favour of gestrinone. No major adverse reactions occurred but menstrual disturbance, acne and non-specific side-effects were all more common with gestrinone. Gestrinone is superior to placebo in the relief of mastalgia. Further evaluation requires randomized comparison with established treatments.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK